Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
Notice Number: NOT-NS-06-008
Release Date: June 12, 2006
National Institute of Neurological Disorders and Stroke (NINDS) (http://www.ninds.nih.gov/)
National Institute of Mental Health (NIMH) (http://www.nimh.nih.gov/)
The UC Davis/NINDS/NIMH NeuroMab facility (http://www.neuromab.org) has been established to generate and distribute, at low cost to neuroscientist end users, high-quality, validated mouse monoclonal antibodies against molecular targets found in the nervous system (NeuroMabs). NeuroMabs are suitable for 1) protein localization studies in the adult, developing and pathological nervous system, 2) biochemical analyses of subunit composition and post-translational modifications of native nervous system proteins, and 3) proteomic analyses of native nervous system protein networks.
The NeuroMab facility was funded in mid-July 2005 for a five-year period with the goal of making monoclonal antibodies to 250-500 nervous system proteins. An initial emphasis is on selecting as targets, membrane proteins (receptors/channels/transporters), membrane-associated scaffolds and synaptic proteins, other neuronal signaling molecules, and proteins with established links to disease states. These NeuroMabs will then be produced on a large scale and made available to the neuroscience research community at low cost (http://www.neuromab.org/PriceList1.htm) in the form of tissue culture supernatants, ascites, or purified immunoglobulins. The current NeuroMab catalog contains NeuroMabs against approximately 60 brain targets, many of which are membrane-associated signaling molecules.
The NeuroMab facility is now accepting suggestions for future targets. Through the NeuroMab web site (http://www.neuromab.org/login.php) requesters should supply NeuroMab with a scientific justification as to the biological importance of the target molecule, the importance of these reagents to the national neuroscience community, and the availability and suitability of existing polyclonal and/or monoclonal antibodies. Requesters should also include a list of reagents (synthetic peptides, fusion proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) that could be made available to the NeuroMab staff to facilitate the development and characterization of these NeuroMabs. The NeuroMab advisory board, together with program officials from NINDS and NIMH, will then prioritize your request for inclusion in the NeuroMab queue.
The NeuroMab Facility is also interested in validating and distributing existing monoclonal antibodies to nervous system proteins. If you are interested in contributing your monoclonal antibodies to the NeuroMab Facility, please contact email@example.com.
Specific questions about this Notice should be directed to the IC Contacts listed below:
Randall R. Stewart, Ph.D.
Program Director for Channels, Synapses and Circuits
National Institute of Neurological Disorders & Stroke
National Institutes of Health
6001 Executive Boulevard, Room 2135
Bethesda, MD 20892-9523
Phone: (301) 496-1917
FAX: (301) 402-1501
Beth-Anne Sieber, Ph.D.
Chief, Developmental Neurobiology Program
Division of Neuroscience and Basic Behavioral Science
National Institute of Mental Health
National Institutes of Health
6001 Executive Blvd., Room 7186, MSC 9641
Bethesda, MD 20892-9641
Phone: (301) 443-5288
Fax: (301) 402-4740
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.